Article

Study: Prolapse repair system offers high efficacy rates at 1 year

The Elevate Apical and Posterior Prolapse Repair System (American Medical Systems, Minnetonka, MN) offers anatomic "cure" rates (stage ≤1 prolapse) of 89.2% in patients with apical prolapse and 91.7% in those with posterior vaginal prolapse, according to the results of a 12-month single-arm, prospective multicenter study.

The Elevate Apical and Posterior Prolapse Repair System (American Medical Systems, Minnetonka, MN) offers anatomic "cure" rates (stage ≤1 prolapse) of 89.2% in patients with apical prolapse and 91.7% in those with posterior vaginal prolapse, according to the results of a 12-month single-arm, prospective multicenter study.

The results, presented at the International Continence Society and International Urogynecological Association joint meeting in Toronto, also show that 98.4% of patients treated with the system would recommend the procedure to a friend. The study was conducted at 16 centers in the U.S., Canada, Belgium, and the United Kingdom.

"Our findings indicate that Elevate offers a prolapse repair technique that is safe with low morbidity and minimal postoperative pain," said principal investigator James Lukban, DO, of Eastern Virginia Medical School, Norfolk. "Our study concluded that Elevate Apical and Posterior is effective in terms of anatomic correction and improvement in day-to-day symptoms at 1 year, with ongoing analysis through 24 months."

In the study, 139 women (mean age, 62.5 years) were implanted with the Elevate system, and 12-month follow-up data were available for 126 of them. Among 48 subjects who completed the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire at baseline and 12 months, mean score improved from 34.1±6.1 to 36.5±5.5 (p=.004, paired t-test).

Funding for the study was provided by American Medical Systems.

Look for additional coverage of the ICS/IUGA joint meeting in an upcoming issue of Urology Times.

Related Videos
3d rendered illustration - bladder | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.